Collateral disease research and translational medicine
10.3867/j.issn.1000-3002.2017.10.011
- Author:
JIA ZHEN-HUA
1
Author Information
1. Hebei Yiling Hospital
- Keywords:
translational medicine;
meridian-collateral theory;
major refractory diseases
- From:
Chinese Journal of Pharmacology and Toxicology
2017;31(10):948-948
- CountryChina
- Language:Chinese
-
Abstract:
Translational medicine, a kind of medical scientific practice oriented by patients'demands, emphasizes that basic theoretical study helps enhance clinical effect, transform into new drugs as well as meet major needs of social development and human health. It follows disciplinary development rules of TCM, persists in five-in-one (theory-clinic-new drug-experiment-evidence based) innovative new mode of TCM translational development, accelerates internal transformation of research findings, and promotes clinical effect and disciplinary development driven by the oretical innovation of collateral disease. In terms of the oretical research, establishment of new discipline of TCM collateral disease theory has become a practitioner and typical representative for promotion of TCM industry development. Important position and guiding role of theoretical innovation in disciplinary development has been valued. Systematically constructing ″collateral disease treatment based on syndrome differen?tiation″ and ″meridian-collateral theory″ lay a theoretical foundation for establishment of the discipline. With regard to clinical research, under the guidance of TCM theory-collateral disease theory, systematic researches on Chinese medical pathogenesis, intervention strategy and effective formula of major diseases are conducted; series of innovative Chinese medicines are developed. Through pharmacody?namics study, relevant action mechanisms are investigated and revealed in- depth. Evidence- based medical researches prove that representative activating-collateral drugs developed under guidance of collateral disease theory have great application values in prevention and treatment of major refractory diseases such as ischemic cardio-cerebrovascular disease, arrhythmia, chronic heart failure, influenza, tumors and diabetes, bringing about significant economic and social benefits. In this way, international cooperation is promoted and internationalization process of innovative Chinese medicine is accelerated. USA FDA phase-Ⅱ clinical research of Lianhua Qingwen Capsules has been successfully launched. Guided by inheritance and innovation of conventional theory of TCM, the new five- in- one mode of development is established. Such a mode conforms to disciplinary development rules of TCM, suffi?ciently exerts core driving effect of TCM theory, realizes combination of theoretical innovation with clinical practice, specialty construction with disciplinary development and clinical research with original new drug, as well as powerfully promotes progress of TCM collateral disease discipline.
